Sorin C. DANCİU, Fahad M. IQBAL, Marian F. MANANKİL, Sharat KOUL, Rashmi RAGHUVİR, Cesar J. HERRERA

Metabolic syndrome in younger patients with acute coronary syndrome

Metabolik sendrom (MeS) genç erişkinler arasında epidemik düzeylere ulaşmıştır. Çalışmamızda genç hasta (50 yaş altı) popülasyo- nunda MeS prevalasını saptamayı ve MeSun akut koroner sendrom üzerindeki etkisini araştırmayı hedefledik. Akut koroner send- rom (AKS) nedeniyle ilk kez hastaneye yatırılan hastalara NCEP-ATP III kriterlerinin olup olmaması göz önüne alınarak MeS tanısı konuldu. Diyabetik hastalar çalışmadan dışlandı. Kontrol grubundaki hastalar diyabet veya metabolik sendrom tanısı olmayan bununla birlikte koroner arter hastalığı bulanan hastalardan oluşmaktaydı. Başlangıçta AKS bulunan 212 hastada MeS prevalansı %26 (n=55). Son analize dahil edilen 75 hastanın 55inde MeS (C1) varken, 20 hastada MeS (C2) yoktu. Ortalama yaş, cinsiyet, LDL ve Framingham risk skorları açısından fark bulunamadı. MeS bulunan hastalar anlamlı olarak daha yüksek oranda STEMI ile başvurmuştur (OR 12.67, 95% CI 1.98-78.40, p=0.004) ve hastaların ejeksiyon fraksiyonları belirgin olarak daha düşüktü (45±12% vs. 58±3%, p=0.0001). Geleneksel kardiyovasküler risk faktörlerine sahip olmayan 50 yaş altı ilk AKS atağı ile başvuran genç has- talarda MeS prevalansı yüksek bulundu. MeSu bulunan hasta grubunda STEMI insidansı ve EF düşüklüğü yüksekti.

Akut koroner sendromlu genç hastalarda metabolik sendrom

Metabolic Syndrome (MeS) has reached epidemic proportions among younger individuals. We sought to determine the prevalence of MeS and its influence on the risk of Acute Coronary Syndrome (ACS) in a younger patient population (≤50 years old). Consecutive patients aged < 50 years hospitalized with the first episode of ACS were categorized whether or not they meet the modified NCEP- ATP III criteria for MeS.1 Diabetic patients were excluded. The control group was comprised of subjects with a de novo diagnosis of CAD but without MeS or DM. The prevalence of MeS in the initial sample of 212 patients with ACS was 26% (N=55). Of the 75 subjects included in the final analysis, 55 patients had MeS (C1) and 20 did not (C2). Mean age, sex, LDL, and Framingham risk scores were not significantly different. Patients with MeS were significantly more likely to present with STEMI (OR 12.67, 95% CI 1.98-78.40, P=0.004), and have lower ejection fractions (45±12% vs. 58±3%, p=0.0001). Among patients younger than 50 years presenting with the first episode of ACS, the prevalence of MeS was high even in the absence of traditional cardiovascular risk factors. Increased incidence of STEMI and reduced EFs were more commonly seen among individuals with MeS.

PDF

___

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
2. O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evi- dence-based approach. Mayo Clin Proc 2009; 84(8):741-57.
3.Eckel RH, Grundy SM, Zimmet PZ. The metabolic syn- drome. Lancet 2005; 365(9468):1415-28.
4. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK. Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288(21):2709-16.
5. Kalantzi K, Korantzopoulos P, Tzimas P, Katsouras CS, Goudevenos JA, Milionis HJ. The relative value of meta- bolic syndrome and cardiovascular risk score estimates in premature acute coronary syndromes. Am Heart J 2008; 155(3):534-40.
6. Chobanian AV, Bakris GL, Black HR, et al, the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey. JAMA 2002;287(3):356-9
8. Chung EH, Burran PJ, Sivasankaran S, et al. Prevalence of Metabolic Syndrome in Patients _____ 45 Years of Age with Acute Myocardial Infarction Having Percutaneous Coronary Intervention. Am J Cardiol 2007;100:1052-5.
9. Weinberger I, Rotenberg Z, Fuchs J, Sagy A, Friedmann J, Agmon J. Myocardial infarction in young adults under 30 years: risk factors and clinical course. Clin Cardiol 1987;10(1):9-15.
10. Perski A, Olsson G, Landou C, de Faire U, Theorell T, Hamsten A. Minimum heart rate and coronary atheroscle- rosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 1992;123(3):609-16.
11. Birhan YM, Guray U, Guray Y, et al. Metabolic syndrome is associated with extension of coronary artery disease in patients with non-ST segment elevation acute coronary syndromes. Coron Artery Dis 2005;16(5):287-92.
12. Milionis HJ, Kalantzi KJ, Papathanasiou AJ, Kosovitsas AA, Doumas MT, Goudevenos JA. Metabolic syndrome and risk of acute coronary syndromes in patients younger than 45 years of age. Coron Artery Dis 2007;18(4):247-52.
13. Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 1995;26(3):654-61.
14. Solymoss BC, Bourassa MG, Campeau L, et al. Effect of in- creasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004;93(2):159-64.
15. Butler J, Mooyaart EAQ, Dannemann N,et al. Relation of the metabolic syndrome to quantity of coronary athero- sclerotic plaque. Am J Cardiol 2008;101(8):1127-30.
16. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care 2005;28(10):2508-13.
17. Kohli P, Greenland P. Role of the metabolic syndrome in risk assessment for coronary heart disease. JAMA 2006;295(7):819-21.